Compare SAP SE (SAP) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SAP SE vs Spyre Therapeutics Inc. Common Stock — how do they compare? SAP SE trades at $218.1 (market cap $254.11B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: SAP SE is far larger — about 33.8× Spyre Therapeutics Inc. Common Stock's market cap, and SAP SE pays a 1.33% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold SAP SE for 118 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| SAP | SYRE | |
|---|---|---|
Market Cap | $254.11B | $7.52B |
Volume | 2,139,071 | 1,441,031 |
Sector | Technology | Health |
52-Week High | $280.46 | $108.92 |
52-Week Low | $146.38 | $22.18 |
Typical Hold Time | 118 Days | 0 Days |
Enterprise Value | $252.86B | $6.52B |
Dividend Yield | 1.33% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SAP trades at $220.49, up 1.21% today, with a bullish technical outlook supported by moving averages and a consensus price target of $253.60. The company reported strong revenue growth to $36.80B in 2025 and a net income margin of 20.41%, though Q2 2026 EPS missed expectations. Recent news highlights AI-driven cloud revenue growth and partnerships, while cash flow trends show variability with a net outflow of $1.39B in 2025.
The stock presents upside potential based on analyst targets and robust fundamentals, but risks include competitive pressures in enterprise software and execution challenges in AI integration. Investors should weigh solid profitability against valuation multiples like a P/E of 29.48, which may limit near-term gains if growth moderates.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About SAP SE
Founded in 1972 by former IBM employees, SAP provides database technology and enterprise resource planning software to enterprises around the world. Across more than 180 countries, the company serves 440,000 customers, approximately 80% of which are small to medium-size enterprises.
Read more on SAP →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
